People living with a NTM-Lung Disease in the US
7 out of 10
patients have mucus associated with an NTM infection
ARINA·1 is poised to be a first-line therapy for improving airway hygiene by clearing mucus and decreasing inflammation in NTM-LD. ARINA-1 is positioned to be used prior to antibiotic initiation and during antibiotic therapy.
Approximately 80,000 people in the US have non-tuberculosis mycobacteria (NTM) lung disease. NTM-LD is caused by pulmonary infections with Mycobacterial species other than tuberculosis, such as M. abscessus and M. avium complex. NTM-LD is characterized by excess mucus, chronic cough, and progressive lung damage. It is treated with cycles of long-term cycles of multiple antibiotics. However, there are limited treatment options for patients to clear mucus and improve their quality of life, especially immediately after diagnosis and between rounds of antibiotics. As NTM detection and prevalence increase and rates of antibiotic resistance increase, additional therapies are needed to improve the quality of life of patients and enable mucus clearance.
Phase 2 Clinical Trial
Safety and Efficacy of ARINA-1 in Early NTM-LD
Quality of life, impact of ARINA·1 on bacterial growth, and systemic inflammatory markers
12 Weeks on Therapy
Patient Enrollment Status